A detailed history of Values First Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 2,617 shares of NTLA stock, worth $31,718. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,617
Holding current value
$31,718
% of portfolio
0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$19.72 - $27.36 $51,607 - $71,601
2,617 New
2,617 $53,000
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $56,643 - $76,238
1,701 New
1,701 $63,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $921M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.